Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.26)
# 2,759
Out of 4,996 analysts
113
Total ratings
50%
Success rate
-4.53%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $800 → $825 | $760.55 | +8.47% | 7 | Sep 24, 2025 | |
| HCAT Health Catalyst | Maintains: In-Line | $3 → $4 | $2.80 | +42.86% | 8 | Aug 28, 2025 | |
| HSIC Henry Schein | Upgrades: Outperform | $83 | $66.04 | +25.68% | 1 | Aug 26, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $200 → $190 | $153.71 | +23.61% | 9 | Aug 13, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $5 → $7 | $8.68 | -19.35% | 9 | Aug 8, 2025 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $60 | $48.46 | +23.81% | 1 | Aug 6, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $300 | $280.61 | +6.91% | 6 | Jul 25, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $7 → $8 | $8.16 | -1.96% | 4 | Jul 9, 2025 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $28 | $23.98 | +16.76% | 4 | Jul 9, 2025 | |
| NVST Envista Holdings | Maintains: Outperform | $19 → $23 | $20.35 | +13.02% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $180 | $179.56 | +0.25% | 6 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $1.09 | +175.23% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $70 | $74.40 | -5.91% | 8 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $200 | $126.19 | +58.49% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $175 → $180 | $188.99 | -4.76% | 3 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $75.77 | -14.21% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $12.50 | +60.00% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $37.56 | -4.15% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $4.53 | +479.47% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.94 | +280.71% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.03 | +441.87% | 2 | Jan 4, 2022 |
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $760.55
Upside: +8.47%
Health Catalyst
Aug 28, 2025
Maintains: In-Line
Price Target: $3 → $4
Current: $2.80
Upside: +42.86%
Henry Schein
Aug 26, 2025
Upgrades: Outperform
Price Target: $83
Current: $66.04
Upside: +25.68%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $200 → $190
Current: $153.71
Upside: +23.61%
Fortrea Holdings
Aug 8, 2025
Maintains: In-Line
Price Target: $5 → $7
Current: $8.68
Upside: -19.35%
Hinge Health
Aug 6, 2025
Maintains: Outperform
Price Target: $50 → $60
Current: $48.46
Upside: +23.81%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $285 → $300
Current: $280.61
Upside: +6.91%
Teladoc Health
Jul 9, 2025
Maintains: In-Line
Price Target: $7 → $8
Current: $8.16
Upside: -1.96%
Privia Health Group
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $23.98
Upside: +16.76%
Envista Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $20.35
Upside: +13.02%
Jul 9, 2025
Maintains: Outperform
Price Target: $170 → $180
Current: $179.56
Upside: +0.25%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $1.09
Upside: +175.23%
Jul 9, 2025
Upgrades: Outperform
Price Target: $50 → $70
Current: $74.40
Upside: -5.91%
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $126.19
Upside: +58.49%
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $188.99
Upside: -4.76%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $75.77
Upside: -14.21%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $12.50
Upside: +60.00%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $37.56
Upside: -4.15%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $4.53
Upside: +479.47%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.94
Upside: +280.71%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.03
Upside: +441.87%